Mexiletine Hydrochloride Capsules

**Type of Posting**  Revision Bulletin  
**Posting Date**  24-Jun-2022  
**Official Date**  1-Jul-2022  
**Expert Committee**  Small Molecules 2

In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 2 Expert Committee has revised the Mexiletine Hydrochloride Capsules monograph. The purpose of this revision is to add *Dissolution Test 2* to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test. Labeling information has been incorporated to support the inclusion of *Dissolution Test 2*.

* Dissolution Test 2 was validated using the µBondapak C18 brand of column with L1 packing. The typical retention time for mexiletine is about 5 min.

Additionally, minor editorial changes have been made to update the monograph to current *USP* style.

The Mexiletine Hydrochloride Capsules Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact Robyn Fales, Senior Scientist I (240-221-2047 or rmp@usp.org).